GlassScriptPhysician profile
Mary E Lott
NPI 1629294665
$1,997.30
in general payments reported to CMS, 2019-2025
25 companies · $381 in 2025
The $381 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.64 · 2020: $107 · 2021: $296 · 2022: $274 · 2023: $304 · 2024: $576 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $315.66 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $189.76 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $170.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $160.71 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Cranial Technologies, INC | $145.72 | 2021-2024 | Doc Band |
| Pfizer INC. | $126.20 | 2022-2024 | |
| Sanofi Pasteur INC. | $102.93 | 2021-2025 | |
| Sobi, INC | $99.45 | 2022-2023 | |
| Tris Pharma INC | $87.47 | 2020-2025 | Onyda Xr, Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $73.31 | 2023-2025 | Ycanth |
| Supernus Pharmaceuticals, INC. | $68.86 | 2023-2025 | Qelbree, Qelbree |
| Alk-Abello, INC | $62.19 | 2025 | Neffy, Ragwitek, Odactra |
| Collegium Pharmaceutical, INC. | $49.98 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $47.41 | 2020-2022 | |
| Corium, LLC | $46.28 | 2023-2024 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.35 | 2025 | |
| Vertical Pharmaceuticals, LLC | $39.35 | 2024-2025 | Relexxii |
| Seqirus USA INC | $36.09 | 2021-2025 | Flucelvax |
| Nestle Healthcare Nutrition INC. | $34.37 | 2021-2023 | |
| Abbott Laboratories | $23.12 | 2024 | Id Now Strep A 2 |
| Aytu Biopharma, INC. | $20.53 | 2021 | |
| Acadia Pharmaceuticals INC | $16.65 | 2023 | Daybue |
| Phadia US INC. | $14.17 | 2024 | Immunocap |
| Kaleo, INC. | $12.50 | 2021 | |
| Genentech USA, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.